Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis

Cancer Research

Volumn 75, Issue 12, 2015, Pages 2541-2552

  Wettersten, Hiromi I ^a,i   Hakimi, A Ari ^b   Morin, Dexter ^c   Bianchi, Cristina ^d   Johnstone, Megan E ^e   Donohoe, Dallas R ^e   Trott, Josephine F ^a   Abu Aboud, Omran ^a   Stirdivant, Steven ^f   Neri, Bruce ^f   Wolfert, Robert ^f   Stewart, Benjamin ^g   Perego, Roberto ^d   Hsieh, James J ^b   Weiss, Robert H ^a,c,h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e UNIVERSITY OF TENNESSEE   (United States)

^f METABOLON INC   (United States)

^g LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; GLUTAMINE; GLUTATHIONE; REACTIVE OXYGEN METABOLITE; TRICARBOXYLIC ACID; TRYPTOPHAN; VON HIPPEL LINDAU PROTEIN;

AEROBIC METABOLISM; ARTICLE; CANCER METABOLIC REPROGRAMMING; CONTROLLED STUDY; FATTY ACID OXIDATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; METABOLISM; METABOLOMICS; PRIORITY JOURNAL; PROTEOMICS; RENAL CANCER CELL LINE; SIGNAL TRANSDUCTION; UPREGULATION; CANCER GRADING; GENETIC TRANSFECTION; KIDNEY TUMOR; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; HUMANS; KIDNEY NEOPLASMS; METABOLOMICS; NEOPLASM GRADING; PROTEOMICS; TRANSFECTION;

EID: 84938970748     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1703     Document Type: Article

References (31)

1. Baker M. Big biology: the 'omes puzzle. Nature 2013; 494: 416-9.
2. Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol 2011; 8: 22-33.
3. Aboud OA, Weiss RH. New opportunities from the cancer metabolome. Clin Chem 2013; 59: 138-46.
4. Perroud B, Ishimaru T, Borowsky AD, Weiss RH. Grade-dependent proteomics characterization of kidney cancer. Mol Cell Proteomics 2008; 8: 971-85.
5. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 2006; 5: 64.
6. Ganti S, Taylor SL, Abu AO, Yang J, Evans C, Osier MV, et al. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res 2012; 72: 3471-9.
7. Kim K, Taylor SL, Ganti S, Guo L, Osier MV, Weiss RH. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS 2011; 15: 293-303.
8. Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, et al. Urine metabolomics analysis for kidney cancer detection and bio-marker discovery. Mol Cell Proteomics 2009; 8: 558-70.
9. Bianchi C, Bombelli S, Raimondo F, Torsello B, Angeloni V, Ferrero S, et al. Primary cell cultures from human renal cortex and renal-cell carcinoma evidence a differential expression of two spliced isoforms of Annexin A3. Am J Pathol 2010; 176: 1660-70.
10. Villas-Boas SG, Hojer-Pedersen J, Akesson M, Smedsgaard J, Nielsen J. Global metabolite analysis of yeast: evaluation of sample preparation methods. Yeast 2005; 22: 1155-69.
11. Laich A, Neurauter G, Widner B, Fuchs D. More rapid method for simultaneous measurement of tryptophan and kynureninebyHPLC. Clin Chem 2002; 48: 579-81.
12. Inoue H, Hwang SH, Wecksler AT, Hammock BD, Weiss RH. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther 2011; 12: 827-36.
13. Fong MY, McDunn J, Kakar SS. Metabolomic profiling of ovarian carcinomas using mass spectrometry. Methods Mol Biol 2013; 1049: 239-53.
14. Evans AM, Dehaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009; 81: 6656-67.
15. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
16. Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, et al. Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 2003; 3: 1620-32.
17. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66: 8927-30.
18. Firth JD, Ebert BL, Ratcliffe PJ. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem 1995; 270: 21021-7.
19. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008; 14: 4726-34.
20. Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 2013; 13: 227-32.
21. Schreurs M, Kuipers F, van der Leij FR. Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome. Obes Rev 2010; 11: 380-8.
22. Ganti S, Taylor S, Kim K, Hoppel CL, Guo L, Yang J, et al. Urinary acylcarnitines are altered in kidney cancer. Int J Cancer 2012; 130: 2791-800.
23. Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, et al. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One 2010; 5: e10696.
24. Paillasse MR, de MP, Amouroux G, Mhamdi L, Poirot M, Silvente-Poirot S. Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion. J Lipid Res 2009; 50: 2203-11.
25. Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D, et al. Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res 2012; 18: 5888-901.
26. Martino JJ, Wall BA, Mastrantoni E, Wilimczyk BJ, La Cava SN, Degenhardt K, et al. Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells. Oncogene 2013; 32: 4366-76.
27. Gameiro PA, Yang J, Metelo AM, Perez-Carro R, Baker R, Wang Z, et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab 2013; 17: 372-85.
28. Adam W, Simpson DP. Glutamine transport in rat kidney mitochondria in metabolic acidosis. J Clin Invest 1974; 54: 165-74.
29. Chung KT, Gadupudi GS. Possible roles of excess tryptophan metabolites in cancer. Environ Mol Mutagen 2011; 52: 81-104.
30. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
31. Okamoto K, Toyokuni S, Kim WJ, Ogawa O, Kakehi Y, Arao S, et al. Overexpression of human mutT homologue gene messenger RNA in renal-cell carcinoma: evidence of persistent oxidative stress in cancer. Int J Cancer 1996; 65: 437-41.